Intravitreal Aflibercept in Neovascular Age-related Macular Degeneration (nAMD): an Observational Study Assessing Patient Relevant Outcomes, Real-world Treatment Pattern and Effectiveness
Phase of Trial: Phase IV
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms ANDROMEDA
- Sponsors Bayer
- 04 Feb 2019 Status changed from not yet recruiting to recruiting.
- 07 Jan 2019 Planned initiation date changed from 31 Dec 2018 to 31 Jan 2019.
- 26 Oct 2018 New trial record